XML 65 R41.htm IDEA: XBRL DOCUMENT v3.6.0.2
Research Agreements (Details)
$ in Thousands, € in Millions
1 Months Ended 12 Months Ended
Feb. 21, 2013
USD ($)
Feb. 21, 2013
EUR (€)
Apr. 30, 2015
USD ($)
Apr. 30, 2015
EUR (€)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Research Agreements              
Research and development expense         $ 107,406 $ 68,280 $ 45,719
Accrued Research Costs, Current         1,228 2,898  
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Per patient costs for enrolled patients              
Research Agreements              
Research and development expense         $ 2,500 $ 5,400 $ 9,600
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Maximum | Per patient costs for enrolled patients              
Research Agreements              
Period for which research and development expense is recognized         19 months    
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Minimum | Per patient costs for enrolled patients              
Research Agreements              
Period for which research and development expense is recognized         9 months    
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Nordic | Maximum              
Research Agreements              
Amount of euro-denominated payments required over the course of clinical trial $ 12,500 € 11.9          
Amount of U.S. dollar-denominated payments required over the course of clinical trial $ 1,100            
Clinical Trial Services Agreement | NB-3 Amendment | Abaloparatide-SC Phase 3 Extension Clinical Study | Nordic | Maximum              
Research Agreements              
Amount of euro-denominated payments required over the course of clinical trial     $ 4,300 € 4.1      
Clinical Trial Services Agreement | Letter of Intent | Abaloparatide-SC Phase 3 Extension Clinical Study | Nordic              
Research Agreements              
Initial term provided for standard of care treatment 6 months 6 months          
Additional term provided for standard-of-care treatment 18 months 18 months